Last edition
News about
Pharmexcil and Department of Commerce Hold Regional Outreach Program in Mumbai
The Department of Commerce hosted a Regional Outreach Program and press interaction at Pharmexcil’s Mumbai office, highlighting the growth and achievements of India’s pharmaceutical exports over the past 12 years.
Lilly's Oral GLP-1 Foundayo Shows Superior A1C Control and Weight Loss in Type 2 Diabetes
Lilly’s oral GLP-1 drug Foundayo (orforglipron) delivered superior A1C control and weight loss in 3 pivotal Type 2 Diabetes (T2D) trials, outperforming oral semaglutide and helping more patients achieve glycemic targets.
NIH Identifies Cells that Protect against Inflammatory Bowel Disease
The National Institutes of Health (NIH) researchers have identified regulatory cells that help protect against Inflammatory Bowel Disease (IBD), a discovery that could lead to improved diagnosis, treatment, and disease management strategies.
GSK Enters Agreement to Acquire Nuvalent
GSK has agreed to acquire Nuvalent in a multi-product oncology deal that strengthens its lung cancer portfolio with two late-stage, potential best-in-class therapies—zidesamtinib and neladalkib—for non-small cell lung cancer.
Syntax Bio and Mayo Clinic Partner on Type 1 Diabetes Cell Therapy
Syntax Bio and Mayo Clinic have partnered to accelerate the development of stem cell-derived pancreatic cell therapies for Type 1 Diabetes (T1D). The collaboration aims to advance regenerative medicine approaches that could restore insulin-producing cells.
Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data
Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.
EU Approves Sanofi's Sarclisa SC as First On-Body Injector Cancer Therapy
Sanofi’s Sarclisa subcutaneous has received EU approval as the first anticancer therapy delivered via an On-Body Injector (OBI). Administered through the CirCLIQ OBI, the treatment offers flexible home or outpatient use for multiple myeloma patients while maintaining efficacy across all approved Sarclisa indications and combinations.
Life Biosciences Doses First Patient in Phase 1 ER-100 Optic Neuropathy Trial
Life Biosciences has dosed the first patient in its phase 1 trial of ER-100, an investigational epigenetic restoration therapy for glaucoma and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). The study marks a key milestone in evaluating a novel approach that targets the underlying causes of age-related vision loss.
Commerce Minister Invites Global Pharma Companies to Partner India's Growth Story
Union Commerce Minister Piyush Goyal has invited global pharmaceutical companies to partner with India’s rapidly growing healthcare sector, highlighting the country’s 7.7 percent economic growth and its transition from a generics-led market to an innovation-driven pharmaceutical hub.
Roche and Nurix Partner to Develop BTK Degrader Bexobrutideg
Roche and Nurix Therapeutics have partnered to develop and commercialise bexobrutideg, a potential best-in-class BTK degrader for B-cell malignancies, chronic spontaneous urticaria, and Multiple Sclerosis (MS), aiming to overcome resistance to current BTK inhibitors.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy